Archive: 01/09/2015
Absorbable stents prove non-inferior to metal in STEMI study
A drug-eluting coronary stent made of absorbable material performed similarly to the gold-standard metal one in a non-inferiority trial among patients with the more serious type of heart attack known as ST-segment elevation ...
Sep 1, 2015
No benefit to prolonging bivalirudin after PCI
Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the ...
Sep 1, 2015
Non-invasive blood flow measurements reduce invasive tests in chest pain patients
According to results of the PLATFORM (Prospective LongitudinAl Trial of FFRCT: Outcome and Resource Impacts) trial, a test known as FFRCT can obviate the need for invasive tests in up to 61% of patients who have chest pain ...
Sep 1, 2015
Absorbable matrix does not prevent cardiac remodelling
An investigational material known Bioabsorbable Cardiac Matrix (BCM) that is injected through the coronary artery to prevent cardiac remodelling in heart attack patients had no significant effect compared to a saline placebo, ...
Sep 1, 2015
Central sleep apnoea device increases mortality in heart failure
Adaptive servo-ventilation (ASV) therapy increases mortality and should not be used to treat central sleep apnoea in heart failure patients with reduced ejection fraction, the SERVE-HF trial shows.
Sep 1, 2015
Automated pulmonary congestion alert no benefit in heart failure trial
Heart failure patients whose implantable cardioverter defibrillators (ICDs) include an automated alert when too much fluid accumulates in their lungs did not have improved outcomes compared to patients with regular ICDs, ...
Sep 1, 2015
Largest study to date shows no benefit to gene transfer therapy in heart failure
Gene transfer therapy aimed at correcting an enzyme abnormality involved in myocardial contraction and relaxation did not improve outcomes in heart failure patients with reduced ejection fraction, results of the CUPID 2 study ...
Sep 1, 2015
Antiparasitics for Chagas cardiomyopathy
A 40 to 80 day treatment with the antiparasitic medication benznidazole significantly reduced parasite activity in the blood, but not the progression of serious heart problems over a 5-year period among patients with established ...
Sep 1, 2015